Avacta Ships SARS-COV-2 Affimer Reagents to Cytiva and Adeptrix
Drug Discovery Today
MAY 13, 2020
Cambridge and Wetherby, UK, 11 May 2020: Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.
Let's personalize your content